软骨基因表达的调控-猫眼课题宝

软骨基因表达的调控

批准号：

7485887

负责人：

LINDA J SANDELL

金额：

$0.86万

依托单位：

WASHINGTON UNIVERSITY

依托单位国家：

美国

项目类别：

财政年份：

2007

资助国家：

美国

项目状态：

已结题

起止时间：

2007-09-01 至 2010-06-30

来源：

https://reporter.nih.gov/project-details/7485887

关键词：

Adipose tissue Adult Alternative Splicing Appendix Applications Grants Binding Biological Models CCAAT-Enhancer-Binding Proteins Cartilage Cells Chick Embryo Child Chondrocytes Chondrogenesis Clinical Trials Collaborations Collagen Gene Data Development Development Plans Disease Dorsal EWS/FLI 1 Type 1 antisense oligonucleotide Embryo Excision Exons Extracellular Matrix Face Family member Gene Expression Gene Expression Regulation Genes Genetic Transcription Grant Health Heterogeneous Nuclear RNA In Vitro Inflammation Inflammatory Instruction Interleukin-1 Intervertebral disc structure Laboratories Length Literature Maintenance Mediating Mesenchymal Messenger RNA Methods Minority Monitor NF-kappa B Nuclear Numbers Osteogenesis Peptide Elongation Factor 1 Phase Play Procollagen Production Progress Reports Protein Isoforms Proteins Publications RNA Sequences RNA Splicing RNA-Binding Proteins Regulation Reporter Research Research Design Resources Role Safety Signal Transduction Skeletal Development Staging Stem cells System TFAP2A gene Testing Trans-Activators Translations Type II Procollagen Undifferentiated Vertebrates Woman Work Xenopus bone morphogenetic protein 2 bone morphogenetic protein 4 cytokine enhancer-binding protein AP-2 human subject in vivo mRNA Precursor notochord novel strategies repaired response transcription factor

项目摘要

项目成果

LINDA J SANDELL的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

............... 5 Other Biographical Sketches (Not to exceed four pages for each - See instructions)) ............................ 9 Resources ......................................................................................................................................................... 19 Research Plan Introduction to Revised Application (Not to exceed 3 pages) ................................................................................................................ Introduction to Supplemental Application (Not to exceed one page) .................................................................................................... A. Specific Aims ............................................................................. _ ....................................................................... :................. 20 / r-- B. Background and Significance ........................................................ I"........................................................................................ I'" C. Preliminary Studies/Progress Report/ _.- (Items A-D: not to exceed 25 pages*) ._ Phase I Progress Report (SBIPJSTTR Phase II ONLY) I* SBIR/STTR Phase I: Items A-D limited to 15 pages. I I I D. Research Design and Methods ............................................... _ ......................................................................................... E. Human Subjects .......................................................................................................................................................................... Protection of Human Subjects (Required if Item 4 on the Face Page is marked "Yes") Inclusion of Women (Required if Item 4 on the Face Page is marked "Yes") ...................................................................... Inclusion of Minorities (Required if Item 4 on the Face Page is marked "Yes") .................................................................... Inclusion of Children (Required if Item 4 on the Face Page is marked "Yes") ...................................................................... Data and Safety Monitoring Plan (Required if Item 4 on the Face Page is marked "Yes" and a Phase I, II, or III clinical trial is proposed ............................................................................................................................................................... F. Vertebrate Animals ..................................................................................................................................................................... G. Literature Cited ............................................................................................................................................................................ H. Consortium/Contractual Arrangements ...................................................................................................................................... I. Consultants ................................................................................................................................................................................. J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY) ............................................................................... Checklist .......................................................... ................................................................................................. Appendix (Five collated sets. No page numbering necessary for Appendix.) Check if Appendix is Included Appendices NOT PERMITTED for Phase I SBIR/S TTR unless specifically solicited. Number of publicaEExis and manusoripts acoepted for publication (not to exceed 10) 10 Other items (list):

期刊论文(0)

专著(0)

科研奖励(0)

会议论文